71 results about "Tumor reduction" patented technology

The invention discloses a compound with anti-tumor activity. The compound has a chemical structural formula as shown in a formula (I). The compound belongs to a novel tetracyclic triterpenoid natural product, has good fat solubility and chemical stability, and can be conveniently extracted from the rhizome of a herbal medicine Polygala fallax Hemsl. And prepared into an oral or injection form. The invention also provides a preparation method and application of the compound. The compound provided by the invention can obviously inhibit the growth of mouse lung cancer and reduce the volume and weight of tumor, and can be used for treating tumor diseases.

Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface phosphatidylserine, alone or in combination with other therapies, are provided. The radiolabeled phosphatidylserine targeting agent delivers radiation to cells that externally present phosphatidylserine, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled phosphatidylserine targeting agent itself increases the cell surface expression of phosphatidylserine, leading to a feed-forward mechanism that drives further accumulation of the phosphatidylserine targeting agent at target lesions to enhance its therapeutic effect.

Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.

Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.

One aspect of the present invention relates to: a conjugate comprising a peptide of a novel sequence and glycyrrhizin; and a pharmaceutical composition for preventing or treating obesity, the composition comprising the conjugate. The conjugate and composition comprising same according to one aspect were found to inhibit hypertrophy of fat cells, increase the cell membrane expression level of ATP-binding cassette transporter A1 (ABCA1), and reduce the secretion of tumor necrosis factor-α (TNF-α). In addition, the conjugate and composition comprising same were found to remain in a greater amount in the blood and have better pharmacokinetic properties than glycyrrhizin used by itself, and thus can be used in the obesity prevention and / or treatment market / industry.

The application belongs to the technical field of medicine, and relates to 3-benzylamino coumarin compounds and application thereof. Experimental results show that the compounds can significantly increase the survival rate of HUVEC cells in a high-sugar environment, and resist blood vessel injury caused by high sugar. The compounds can increase the release amount of NO in HUVEC cells damaged by high sugar, reduce the generation of malondialdehyde, and reduce the generation of tumor necrosis factor alpha.

Disclosed herein are compositions and methods for treating cancer, specifically extensive-stage small-cell lung cancer (ES-SCLC), through the administration of a combination therapy. In some embodiments, the method comprises administering plinabulin, one or more immune checkpoint inhibitors, including but not limited to pembrolizumab, and a regimen of etoposide with a platinum-based agent (EP). The disclosed methods enhance tumor reduction, prolong progression-free survival, and improve overall treatment efficacy compared to traditional therapies.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The invention belongs to the technical field of biological medicines, and particularly relates to a pharmaceutical composition containing carboxamide triazole or pharmaceutically acceptable salts thereof and application of the pharmaceutical composition in preparation of medicines for preventing or treating fibrosis-related diseases. Specifically, the invention discovers that the carboxylamine triazole orotate (CTO) can directly inhibit fibroblast collagen generation and cross-linking maturation, so that the fibrosis degree is reduced; when the polypeptide is combined with a PD-1 antibody, collagen deposition in tumor tissues can be reduced by inducing normalization of a tumor matrix in a synergistic manner, the tumor permeation concentration of chemotherapeutic drugs is remarkably enhanced, and the anti-tumor curative effect is improved. The invention can be applied to the treatment of various matrix dense solid tumors including pancreatic cancer, breast cancer, colorectal cancer and lung adenocarcinoma, and is expanded for intervention of fibrosis-related diseases, thereby providing a new treatment strategy for improving the efficacy of chemotherapeutic drugs and improving immunotherapy response through targeted matrix remodeling.

The invention relates to the field of biological medicines, in particular to a PD-L1 targeting polypeptide and application thereof. The present invention provides a PD-L1 targeting polypeptide, which is characterized in that the polypeptide comprises a first fragment and a second fragment, the first fragment is used for binding with PD-L1, the second fragment is used for mediating degradation of PD-L1 in lysosome, and the first fragment comprises an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. The polypeptide provided by the invention can promote the degradation of PD-L1 protein through lysosome, reduce the content of PD-L1 expressed by tumor cells and / or exosomes, fundamentally avoid and reduce the interaction between PD-L1 and PD-1, and have better inhibition effect and treatment effect.

The inventors have prepared a novel anti-Cath-D antibody (F1M1) that can reduce tumor growth in a Cath-D secreting basal-like TNBC cell line with strong immune infiltration, without significant toxicity. The F1M1 antibody prevents recruitment of immunosuppressive M2 polarized tumor-associated macrophages (TAMs) and induces activation of natural killer cells in the tumor, and the F1M1 also enhances activation of antitumor M1 polarized TAM, recruitment and maturation of conventional cDC1 dendritic cells in the tumor to promote antigen presentation and reduce depletion marker expression of CD4 + and CD8 + T cells in the tumor and drainage lymph nodes. It is worthy of noting that the affinity of the antibody F1M1 to Cath-D is better than that of the antibody F1 prepared by the inventor in advance. The inventors also have prepared a novel Fc-optimized F1M1-Fc + human antibody which can promote ADCC induction of cancer cells and CAF, improve anti-tumor efficacy, and trigger recruitment, activation and cytotoxic activity of NK cells in tumors. The F1M1-Fc + F1M1-Fc + can inhibit the growth of MDA-MB-231 and SUM159 TNBC cell xenografts and two TNBC-PDX (one of the TNBC-PDX is resistant to neoadjuvant chemotherapy), and has no obvious toxicity. In addition, the F1M1-Fc < + > improves the treatment effect of the paclitaxel and enzalutamide combined medicine. Thus, the present invention relates to anti-cathepsin-D antibodies and their use in the treatment of cancer, in particular triple negative breast cancer.

A method for treating head and neck tumors is provided, specifically relating to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for treating head and neck tumors, wherein the compound of formula (I) produces good efficacy in reducing tumor growth or even eliminating tumors.

The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for reducing adverse reactions after radiotherapy and chemotherapy of tumor patients and a preparation method thereof, comprising the following components in parts by weight: Radix Bupleuri 6-9 parts, Radix Paeoniae Alba 6-9 parts, Rhizoma Atractylodis Macrocephalae 6-9 parts, Poria 6-9 parts, Angelica sinensis 6-9 parts, Zingiber officinale 3 parts, Radix Rehmanniae Recens 3-6 parts, Gardenia 3-6 parts, Radix Paeoniae Rubra 3-6 parts, Radix Paeoniae Alba 12-20 parts, Rhizoma Chuanxiong 6 parts, and Radix Glycyrrhizae 3-6 parts; the traditional Chinese medicine composition can improve the spirit and movement state of mice, and the weight and food intake of mice are obviously increased, the number of dead mice is significantly reduced, and the tumor volume and weight of mice are significantly reduced; the spleen and thymus indexes, the number of white blood cells, red blood cells and platelets in peripheral blood, and the hemoglobin content are all significantly increased; the number of bone marrow cells and the CD4 + T / CD8 + T cell ratio in peripheral blood are all significantly increased; when applied to clinical patients, the traditional Chinese medicine composition can reduce adverse reactions after radiotherapy and chemotherapy of tumor patients, and has a broad application prospect.

The invention discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors, belongs to the technical field of anti-tumor traditional Chinese medicines, and discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-25 parts of ginseng, 15-18 parts of selfheal, 12-18 parts of seaweed, 12-19 parts of astragalus membranaceus, 10-16 parts of angelica sinensis, 18-30 parts of oldenlandia diffusa, 10-15 parts of fleece-flower root, 10-14 parts of poria cocos, 10-16 parts of thunberg fritillary bulb, 8-14 parts of pseudobulbus cremastrae seu pleiones and 8-17 parts of curcuma zedoary. Through the specific pharmacological action, growth and proliferation of thyroid tumor cells are inhibited, the development speed of tumors can be slowed down, the malignancy degree of the tumors can be reduced, apoptosis of the thyroid tumor cells can be induced, and the number of the tumor cells can be effectively reduced by inducing apoptosis of the tumor cells, so that the anti-tumor purpose is achieved.

This invention discloses a photothermal synergistic tumor stem cell inhibition system, its preparation method, and its applications. Addressing the current lack of effective treatments for large / unresectable GBM and its strongly immunosuppressive microenvironment, this invention constructs an injectable hydrogel platform (MIN-PPIC@iGel) integrating multiple key functions. This platform achieves a synergistic therapeutic model involving photothermal ablation for local tumor reduction, inhibition of residual GBM stem cells (GSCs), and activation of dendritic cells (DCs)-mediated anti-tumor immunity. Cellular experiments show that this invention can synergistically kill GL261 cells, significantly inhibit tumor stem cells and malignant phenotypes, induce significant ICD, and enhance DC maturation and activation effects. In a large-volume orthotopic GBM mouse model, a single intratumoral injection of MIN-PPIC@iGel combined with short-term near-infrared light irradiation doubled survival; further combination with antibody therapy unexpectedly achieved long-term tumor-free survival in 50% of mice, providing a new strategy for the local treatment of unresectable GBM.

This invention belongs to the field of novel pharmaceutical uses, and more specifically, relates to the application of ethyl acetate extract of turmeric in the preparation of drugs for treating colorectal cancer. The preparation method of the extract is as follows: turmeric slices are soaked overnight in 15 times their weight of a 70% (v / v) ethanol solution, refluxed at 85°C three times, 2 hours each time. The extracts are combined and concentrated until no alcohol odor remains. The extract is then dried to constant weight to obtain the total extract. The total extract is reconstituted with water and extracted three times with ethyl acetate at an equal volume ratio. The extracts are combined and dried to constant weight to obtain the final product. Experimental results show that this extract is particularly effective in improving disease activity index, restoring colon length, reducing tumor number, and alleviating histopathological damage, and has no significant toxicity to major organs. This extract can be formulated into oral or injectable preparations, providing a new natural drug candidate for the treatment of colorectal cancer.

The application discloses a kind of dual targeting / drug-loaded reduction-sensitive nano-carrier, and the micelle is formed by the micelle of block polymer by solvent evaporation method, and the multi-block polymer is Tel-PEG-ss-PCL, the hydrophilic end of which is PEG with targeting group Tel, and the hydrophobic end is PCL, which is a core-shell structure, the core is the hydrophobic end PCL, and the shell is the hydrophilic block with targeting group Tel.The nano-carrier selects the polymer micelle with hydrophilic end polyethylene glycol and hydrophobic end polycaprolactone as drug carrier to improve the problem of poor water solubility of drug;Tel, an angiotensin II type receptor (AT1R) ligand, is used to simultaneously target CAFs and tumor cells overexpressing AT1R, kill tumor cells and CAFs, and double drug loading to overcome drug resistance;Meanwhile, disulfide bond is used to respond to high concentration glutathione (GSH) in tumor cells to achieve precise control release of drug in cells.The nano-carrier realizes the treatment effect of solubilization of poorly soluble drug, tumor and CAFs dual targeting and reversal of drug resistance.

The invention relates to a thermo-sensitive hydrogel drug sustained-release stent for jointly loading a hypotensive drug and a chemical / immunotherapy drug, which is prepared from a thermo-sensitive material and loads three drug components, namely losartan, oxaliplatin and an immune checkpoint inhibitor. The temperature-sensitive hydrogel can form gel in situ under the triggering of body temperature, and meanwhile, the acting time of the medicine on a target part is prolonged. The antihypertensive drug losartan potassium can reduce tumor interstitial substances, reduce tumor solid stress, relieve vascular compression in tumors and improve tumor hypoxia. Meanwhile, the chemotherapeutic drug oxaliplatin can induce tumor immunogenic cell death, and the tumor immunosuppressive microenvironment is effectively relieved. The immune checkpoint inhibitor can be used for accurately blocking the combination of the PD-L1 and the PD-1 and activating the T cell mediated anti-tumor immune response. According to the present invention, the potent anti-tumor immune response can be triggered, the excellent tumor inhibition effect can be achieved, the strong far-end effect can be even induced, and the growth of the far-end tumor can be effectively inhibited.

Described herein is a new mitochondrial peptide. This small peptide is capable of modulating cancer, through a variety of mechanisms including autophagy / apoptosis, reduction of tumor cell viability, inducing inflammatory response in senescent cells and conversion of macrophage cell type. Administration of the peptide, its analogs and derivatives thereof, are likely to be effective treatments for cancer therapy, including generation of synthetic analogs that further enhance or abrogate activity relative to the peptide.

The application belongs to the field of biological pharmacy, and particularly relates to application of a Caerin polypeptide combined with a dendritic cell vaccine in preparation of a drug for treating breast cancer. The application finds that F1 / F3 significantly inhibits proliferation of 4T-1 cells and induces cell death in vitro, significantly inhibits growth of a primary tumor, reduces lung metastasis, and prolongs overall survival in vivo, and inoculation of a DC vaccine loaded with a tumor-related antigen can reduce tumor growth and enhance T cell activation in draining and non-draining lymph nodes. Compared with a vaccine loaded with a whole antigen (DCV1), a DC vaccine (DCV2) combined with F1 / F3 induced 'programmed death antigen' exhibits stronger anti-tumor activity, although TNF-alpha and IL-12 secretion thereof is lower. Therefore, the application combines the F1 / F3 polypeptide with the DCV2 to prepare a drug for treating breast cancer, effectively improves the treatment effect on the tumor, and highlights the importance of a combined immunotherapy strategy.

Provided are pharmaceutical compositions for reducing a tumor burden in a subject having a cancer comprising a combination therapy comprising a therapeutically effective dose of a modified CD2 polypeptide derived from human or rat domain one of CD2 polypeptide and a second therapeutic agent comprising an immune checkpoint inhibitor. Also provided are methods of inhibiting or reducing tumor growth and methods of synergistically increasing the activity of an anti-PD-L1 immunotherapeutic in a subject having a cancer comprising administering the pharmaceutical compositions.

The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, one or more agents that decrease the production of tumor necrosis factor-alpha (TNF-α), decrease the CCL2, and decrease the interleukin-1 beta (IL-1β) responsible for low grade chronic inflammation.In some embodiments, the composition comprises: epicatechin present in an amount of about 0.25% to about 1% w / w of the composition; EGCG present in an amount of about 0.01% to about 0.1% w / w of the composition; lycopene present in an amount of about 1% to about 3% w / w of the composition; quercetin present in an amount of about 0.1% to about 1% w / w of the composition; luteolin present in an amount of about 0.1% to about 1% w / w of the composition; vitamin A present in an amount of about 1% to about 7.5% w / w of the composition; vitamin C present in an amount of about 40% to about 77% w / w of the composition; and vitamin E present in an amount of about 15% to about 40% w / w of the composition. Such compositions are useful for improving LGCI by decreasing TNF-α, CCL2, and IL-1β concentration.

The present invention is applicable to the technical field of plant extraction and separation. Provided is a polysaccharide compound having a clear molecular structure and an anti-tumor effect. The polysaccharide compound is used for the treatment of patients with advanced cancers (patients who have lost surgical conditions, have a survival time of only three to six months, and are still eligible for chemotherapy), and has a molecular formula of: (C30H50O25)n. The active ingredient of Ganoderma is extracted under high temperature and high pressure to obtain the pharmacophore polysaccharide, i.e., the polysaccharide compound. The polysaccharide having the pharmacophore has good water solubility, is easily absorbed by a human body, has an anti-tumor efficacy, and is capable of preventing human tumorigenesis. Particularly, when being used in combination with a chemotherapeutic drug, the polysaccharide can eliminate toxic side effects on a human body caused by the chemotherapeutic drug, control and reduce the tumor mass, and reduce and eliminate tumor cells, which effects are all supported by corresponding experimental data.

The invention provides a traditional Chinese medicine preparation for early nasopharynx cancer, and belongs to the technical field of traditional Chinese medicine preparation. According to the traditional Chinese medicine preparation, American ginseng and prepared rehmannia root are used as monarch drugs, Chinese yam, rhizoma polygonati, adenophora tetraphylla, oviductus ranae and white hyacinth beans are used as ministers, lucid ganoderma, radix puerariae, radix angelicae, horsetail and amomum kravanh are used as assistants, Chinese dates are used as guides, and all the drugs are combined to achieve the effects of supporting healthy energy, reinforcing qi, nourishing yin, invigorating the spleen, tonifying the kidney, resolving dampness and dredging orifices. In-vitro experiment results show that the traditional Chinese medicine preparation has obvious proliferation and migration inhibition effects and apoptosis promotion effects on nasopharyngeal carcinoma cells. An in-vivo experiment result shows that the traditional Chinese medicine preparation can improve the adverse reaction of weight loss of a body caused by a traditional chemotherapeutic drug, can effectively reduce the tumor growth speed of a tumor-bearing mouse, remarkably reduces the tumor volume and mass, and has a remarkable inhibition effect on tumor growth. In addition, the traditional Chinese medicine preparation is combined with cis-platinum for use, so that the inhibition effect on tumor growth can be effectively enhanced.

The application discloses a kind of nano-operon for constructing CAR-T cell and its preparation method and application, belong to the field of biological medicine technology.The nano-operon for constructing CAR-T cell of the application includes nanovesicle, the nanovesicle carries CAR protein and the membrane fusion protein of target T cell, the nano-operon can utilize membrane fusion mode, so that the CAR protein is delivered to T cell by the nanovesicle carrying the membrane fusion protein of target T cell, to be able to construct CAR-T cell with tumoricidal activity directly in vivo or in vitro, reduce the waiting time of tumor treatment and reduce the required index requirements of treatment on one hand, on the other hand, effectively reduce the side effects generated in CAR-T cell therapy, realize the alleviation to patient burden.

The present invention provides combination therapy using a first binding agent comprising at least one binding region binding to CD27 in combination with a second binding agent comprising a first binding region binding to CD40 and a second binding region binding to CD137 to reduce progression or prevent progression of a tumor or treating cancer.

The invention discloses application of dendrobium officinale polysaccharide in preparation of a PGC-1alpha signal channel inhibitor, and research shows that dendrobium officinale can regulate and control metabolic gene expression of macrophages in a tumor microenvironment, promote polarization of macrophages M1 and effectively inhibit occurrence and development of tumors; meanwhile, the dendrobium candidum polysaccharide can also promote glycolysis metabolism of tumor-related macrophages, remarkably promote expression of macrophage glycolysis-related genes, inhibit expression of oxidative phosphorylation genes and PGC-1alpha genes, effectively reduce the volume and size of tumors, inhibit PGC-1alpha signal channels in the macrophages and inhibit the growth of tumor cells. In addition, the dendrobium officinale polysaccharide can be used as a PGC-1alpha signal channel inhibitor for preparing antitumor drugs, and a new way is provided for improving the metabolic state in a tumor microenvironment and tumor immunotherapy.

The present application relates to a kind of tetravalent platinum complex, nanoparticle and its preparation method and application, the structural formula of the tetravalent platinum complex is as shown in formula I, wherein, cisplatin, carboplatin or oxaliplatin;N is the integer selected from 1-8. The tetravalent platinum complex or the nanoparticle comprising it can be reduced to divalent platinum counterpart under tumor cell environment, and play tumor cell killing effect, can reduce tumor cell drug resistance, enhance the effect of tumor cell killing, have obvious enhanced anti-tumor immune effect.

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating ovarian cancer, a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw medicinal materials: Astragalus membranaceus (Fisch.) Bunge, Ramulus Cinnamomi, Poria cocos (Schw.) Wolf, Semen Persicae, Gynostemma pentaphyllum (Thunb.) Makino, Radix Moutan, Magnolia officinalis Rehd. et Wils., and Hirudo nipponia Whitfield. The traditional Chinese medicine composition has the effects of benefiting qi and activating blood, removing blood stasis and dredging collaterals. Therefore, the traditional Chinese medicine composition is suitable for patients after surgery or radiotherapy and chemotherapy for ovarian cancer, and is also suitable for patients who cannot tolerate surgery or radiotherapy due to poor physical condition. The traditional Chinese medicine composition has the effects of reducing tumor cell proliferation, regulating tumor immunity, reducing toxicity and increasing efficacy. In the maintenance treatment stage, the traditional Chinese medicine composition can enhance the immunity of patients, prolong the survival period of patients, and improve the life quality of patients.